Antiviral and inflammatory immune signatures in anti-CD20-treated multiple sclerosis: a cross-sectional study. (PubMed, J Neurol) - Oct 16, 2026 - "An immunophenotyping cohort (45 untreated, 25 anti-CD20-treated, all receiving ocrelizumab) was profiled by high-parameter flow cytometry across more than 40 immune populations...sNfL was elevated in untreated pwMS and correlated with MCP-3 at baseline and after EBV stimulation. Anti-CD20 therapy acts on immune circuits beyond B cells, selectively contracting EBV-directed helper T-cell immunity while sparing other antiviral responses, and identifies MCP-3 as a candidate blood marker associated with neuroaxonal injury in pwMS."
Journal • Observational data • CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Infectious Disease • Multiple Sclerosis • Novel Coronavirus Disease • Respiratory Diseases • CD4 • IFNA1 • IL1B • NEFL
|
|
Alice Verdiani; Andrea Misiti; Arcangela Ingrascì; Bruno Gran; Carla Tortorella; Claudio Gasperini; Daniela F Angelini; Elena Olivieri; Emiliano Giardina; Giovanna Borsellino; Gisella Guerrera; Luca Battistini; Marco Salvetti; Maria Chiara Buscarinu; Mario Picozza; Marta Pirronello; Serena Ruggieri; Silvia Corbisiero; Silvia D'Orso
|